Global Licensing agreement

Article

UK firm UltraVision CLPL has agreed on a global licensing agreement with Bausch + Lomb for the marketing and sales of KeraSoft contact lens.

UK firm UltraVision CLPL has agreed on a global licensing agreement with Bausch + Lomb for the marketing and sales of KeraSoft contact lens.

The move will enable UltraVision to distribute the lens globally and reach a wider market. Jerry Warner, Vice President of marketing and general manager at Bausch + Lomb, Global Contact Lens, said: "Extending the KeraSoft technology allows the lab to expand the ability of practitioners to offer life-changing vision correction to a wider range of patients who have a variety of irregular cornea conditions resulting from keratoconus and pellucid marginal degeneration."

The custom-made soft lens has been manufactured from silicone hydrogel materials and has been developed to correct irregular corneas, pellucid marginal degeneration and keratoconus.

Joseph Barr, vice president of Global Clinical and Medical Affairs and Professional Services, Vision Care, Bausch + Lomb, said: “This technology has totally transformed my view of contact lens management of keratoconus and irregular cornea patients. The visual results and enhancement of life are true advances.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.